Telemonitoring to manage side effects from immunotherapy
Part of Cancer, Kidney & urinary, Lungs & breathing, Skin, Women’s health & pregnancy clinical trials.
This trial tests whether using home digital monitoring (telemonitoring) can help people with melanoma, lung, or kidney (renal) cancer manage side effects while on immunotherapy. It may help catch side effects earlier and support you during treatment with nivolumab plus ipilimumab or nivolumab alone.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are older than 18 years.
- You have melanoma, lung cancer, or kidney (renal) cancer.
- You are starting immunotherapy with nivolumab plus ipilimumab, or nivolumab alone.
- You are comfortable using digital tools/computers (for the monitoring).
- You agree to join the telemonitoring program and sign the consent form.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a smartphone app called Vigilant that helps monitor side effects from a melanoma treatment (ipilimumab and nivolumab). You may be able to join if you are about to start this therapy.
This trial tests a program that helps melanoma patients starting immunotherapy track their side effects and get faster access to specialists. The goal is to improve symptom management.
This study checks how well remote (at-home) symptom check-ins work for people with certain cancers. It may help patients and clinicians spot problems earlier and improve day-to-day care during treatment and beyond.
This study is looking at whether a special PET scan (FDG PET/CT) and a blood test that measures ctDNA (cancer DNA in the blood) can help predict how well immune checkpoint inhibitors work in people with advanced melanoma. If you are planning to get treatment with immunotherapy drugs like ipilimumab, nivolumab, or pembrolizumab, you may be able to join.
This trial studies how your immune system “profiles” change while you’re treated with immunotherapy for melanoma. Results may help doctors better understand who benefits from treatment and when.
This trial tests whether tracking your symptoms with a digital app can help manage side effects while you receive two medications (cabozantinib and nivolumab) for advanced clear-cell kidney cancer that hasn't been treated before.
Hear when a new Melanoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.